FDA accepts BioCryst's sNDA for Rapivab in pediatric patients

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said FDA accepted and granted Priority Review to an sNDA for Rapivab peramivir (BCX-1812, RWJ-270201) to treat acute uncomplicated influenza in pediatric patients. The PDUFA date is before the end of September. Rapivab is already approved for the indication in adults...